Company intelligence / Profile preview

VERIGRAFT

Ownership: Private
Employees: ~16
Development stage: Phase 1

Overview

VERIGRAFT has developed a proprietary technology that transforms donated allogeneic tissues into personalized grafts resembling the patient’s own tissue. This approach aims to eliminate transplant rejection and the need for lifelong immunosuppression. The company’s pipeline includes vascular grafts and peripheral nerve repair products in preclinical or early clinical stages.

Therapeutic areas: CardiovascularNeurology
Modalities: Tissue-engineered grafts (personalized veins, arteries, nerves, heart valves)Decellularization and recellularization of allogeneic tissue
Industry: Implantable Medical Devices

Drug pipeline

1 asset

P-TEV

Phase 1

Indications: Chronic venous insufficiency

Beyond the preview

Go deeper on VERIGRAFT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VERIGRAFT.

Explore the full profile